Zaloguj się

Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.

W tym Artykule

  • Podsumowanie
  • Streszczenie
  • Wprowadzenie
  • Protokół
  • Wyniki
  • Dyskusje
  • Ujawnienia
  • Podziękowania
  • Materiały
  • Odniesienia
  • Przedruki i uprawnienia

Podsumowanie

Several methods have been used for analyzing plasma lipoproteins; however, ultracentrifugation is still one of the most popular and reliable methods. Here, we describe a method regarding how to isolate lipoproteins from plasma using sequential density ultracentrifugation and how to analyze the apolipoproteins for both diagnostic and research purposes.

Streszczenie

Analysis of plasma lipoproteins and apolipoproteins is an essential part for the diagnosis of dyslipidemia and studies of lipid metabolism and atherosclerosis. Although there are several methods for analyzing plasma lipoproteins, ultracentrifugation is still one of the most popular and reliable methods. Because of its intact separation procedure, the lipoprotein fractions isolated by this method can be used for analysis of lipoproteins, apolipoproteins, proteomes, and functional study of lipoproteins with cultured cells in vitro. Here, we provide a detailed protocol to isolate seven lipoprotein fractions including VLDL (d<1.006 g/mL), IDL (d=1.02 g/mL), LDLs (d=1.04 and 1.06 g/mL), HDLs (d=1.08, 1.10, and 1.21 g/mL) from rabbit plasma using sequential floating ultracentrifugation. In addition, we introduce the readers how to analyze apolipoproteins such as apoA-I, apoB, and apoE by SDS-PAGE and Western blotting and show representative results of lipoprotein and apolipoprotein profiles using hyperlipidemic rabbit models. This method can become a standard protocol for both clinicians and basic scientists to analyze lipoprotein functions.

Wprowadzenie

Dyslipidemia is the major risk factor of atherosclerotic disease in the world. High levels of low-density lipoproteins (LDLs) and low levels of high-density lipoproteins (HDLs) are closely associated with a high risk of coronary heart disease (CHD)1,2. In the clinical setting, both LDL-cholesterol (LDL-C) and HDL-cholesterol (HDL-C) are routinely measured using an automated analyzer in a clinical laboratory3,4. Despite this, it is essential to analyze lipoprotein profiles in details for the diagnosis of dyslipidemia and the study of lipid metabolism and atherosclerosis in human and experimental animals. Several methods have been reported to analyze plasma lipoproteins such as ultracentrifugation, size exclusion chromatography [fast protein liquid chromatography (FPLC) and high performance liquid chromatography (HPLC)], electrophoresis by agarose and polyacrylamide gels, nuclear magnetic resonance, and selective chemical precipitation using polyanions and divalent cations or other chemicals. In 1950s, Havel’s group first proposed the concept of lipoproteins defined by densities using ultracentrifugation and classified them into chylomicrons (CM), very-low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), LDL, and HDL5 and later on, the method was further modified by other groups6,7. Until now, ultracentrifugation is the most popular and reliable method while the practical protocol is still not available. In this paper, we attempted to describe an easy-to-use protocol for isolating a small scale of plasma using sequential density floating ultracentrifugation originally described previously8. Isolation of seven plasma lipoprotein fractions [VLDL (d<1.006 g/mL), IDL (d=1.02 g/mL), LDLs (d=1.04 and 1.06 g/mL), HDLs (d=1.08, 1.10, and 1.21 g/mL)] enables researchers to make an extensive analysis of both lipoproteins and their compositional apolipoproteins9,10,11. The intact seven consecutive density lipoproteins can be used for analyzing lipoprotein functions and also serving to cell-based in vitro strategies. This protocol should be useful for both clinical diagnosis and basic research. Here we used rabbit plasma as an example to demonstrate this technique while plasma from other species can be applied in the same way.

Protokół

All procedures for rabbit studies were performed with approval of University of Yamanashi Institutional Animal Care and Use Committee (Approved number: A28-39).

1. Plasma separation from rabbit blood

  1. Prepare 1.5 mL microtubes containing 15 µL of 0.5 M EDTA (pH 8.0) for blood collection.
  2. Put a rabbit in a restrainer and puncture an auricular intermediate artery using a 22 gauge needle and collect blood into a tube. Mix the blood with EDTA gently and put them on ice.
  3. Centrifuge the blood tubes at 1,500 x g for 20 min at 4 °C and collect plasma to a new microtube.
    NOTE: 3 mL of blood is enough for collecting 1 mL plasma. If you collect blood from mice or other small animals, you need to pool them.

2. Isolation of plasma lipoproteins

NOTE: The schematic procedure is shown in Figure 1. The preparation method of potassium bromide (KBr) density solutions is shown in Table 1.

  1. Transfer 1 mL of plasma to a polycarbonate ultracentrifuge tube (Figure 2A).
  2. Load these tubes in a fixed angle rotor and centrifuge the plasma at 356,000 x g for 2.5 h at 4 °C (Figure 2B).
    NOTE: For Beckman TLA 120.2 rotor, 356,000 x g (average relative centrifugal field, Av RCF) corresponds to 100,000 rpm.
  3. Cut the tubes using a slicer and then collect the top fraction [VLDL (d<1.006 g/mL)], approximately 200 µL into a new microtube (Figure 2C). Collect the remaining bottom fraction into a new polycarbonate ultracentrifuge tube for the next separation (Figure 2D). Measure the volume and make the total volume to 800 µL by adding the same density solution (d=1.006 g/mL).
    NOTE: Set up a blade to the tube slicer. Adjust the position of the blade at a level between the top fraction (200 µL) and the bottom fraction (800 µL). The viscous precipitant in the bottom fraction should be collected carefully and completely by pipetting in all following steps. If pause, do so after separating the top and bottom fraction in all steps. Store the sample at 4°C until the next centrifugation.
  4. Adjust the bottom fraction (total 800 µL) to d=1.02 g/mL by adding 58.9 µL of d=1.21 g/mL solution and 141.1 µL of d=1.02 g/mL solution (the total volume is 1 mL).
  5. Load these tubes in fixed angle rotor and centrifuge at 356,000 x g for 2.5 h at 4 °C.
  6. Cut the tubes using a slicer and then collect the top fraction [IDL (d=1.02 g/mL)] approximately 200 µL into a new microtube. Collect the remaining bottom fraction into a new polycarbonate ultracentrifuge tube for the next separation. Measure the volume and make the total volume to 800 µL by adding the same density solution (d=1.02 g/mL).
  7. Adjust the bottom fraction (total 800 µL) to d=1.04 g/mL by adding 94.1 µL of d=1.21 g/mL solution and 105.9 µL of d=1.04 g/mL solution (the total volume is 1 mL).
  8. Load these tubes in a fixed angle rotor and centrifuge at 356,000 x g for 2.5 h at 4 °C.
  9. Cut the tubes using a slicer and then collect the top fraction [LDL (d=1.04 g/mL)] approximately 200 µL into a new microtube. Collect the remaining bottom fraction into a new polycarbonate ultracentrifuge tube for the next separation. Measure the volume and make the total to 800 µL by adding the same density solution (d=1.04 g/mL).
  10. Adjust the bottom fraction (total 800 µL) to d=1.06 g/mL by adding 106.7 µL of d=1.21 g/mL solution and 93.3 µL of d=1.06 g/mL solution (the total volume is 1 mL).
  11. Load these tubes in a fixed angle rotor and centrifuge at 356,000 x g for 2.5 h at 4 °C.
  12. Cut the tubes using a slicer and then collect the top fraction [LDL (d=1.06 g/mL)] approximately 200 µL into a new microtube. Collect the remaining bottom fraction into a new polycarbonate ultracentrifuge tube for the next separation. Measure the volume and make the total to 800 µL by adding the same density solution (d=1.06 g/mL).
  13. Adjust the bottom fraction (total 800 µL) to d=1.08 g/mL by adding 123.1 µL of d=1.21 g/mL solution and 76.9 µL of d=1.08 g/mL solution (the total volume is 1 mL).
  14. Load these tubes in a fixed angle rotor and centrifuge at 356,000 x g for 2.5 h at 4 °C.
  15. Cut the tubes using a slicer and then collect the top fraction [HDL2 (d=1.08 g/mL)] approximately 200 µL into a new microtube. Collect the remaining bottom fraction into a new polycarbonate ultracentrifuge tube for the next separation. Measure the volume and make the total to 800 µL by adding the same density solution (d=1.08 g/mL).
  16. Adjust bottom fraction (total 800 µL) to d=1.10 g/mL by adding 145.5 µL of d=1.21 g/mL solution and 54.5 µL of d=1.10 g/mL solution (the total volume is 1 mL).
  17. Load these tubes in a fixed angle rotor and centrifuge at 356,000 x g for 2.5 h at 4 °C.
  18. Cut the tubes using a slicer and then collect the top fraction [HDL2 (d=1.10 g/mL)] approximately 200 µL into a new microtube. Collect the remaining bottom fraction into a new polycarbonate ultracentrifuge tube for the next separation. Measure the volume and make the total to 800 µL by adding the same density solution (d=1.10 g/mL).
  19. Adjust bottom fraction (total 800 µL) to d=1.21 g/mL by adding 0.140 g of potassium bromide (KBr) powder and dissolve it completely. Measure the volume and make them to 1 mL by adding d=1.21 g/mL solution.
  20. Load these tubes in fixed angle rotor and centrifuge at 513,000 x g for 4 h at 4 °C.
    NOTE: For Beckman TLA 120.2 rotor, 513,000 x g (Av RCF) corresponds to 120,000 rpm.
  21. Cut the tubes using a slicer and then collect the top fraction [HDL3 (d=1.21 g/mL)] approximately 200 µL into a new microtube. This is the last step for ultracentrifugation.

3. Dialysis

NOTE: Because the density fractions (except d<1.006 g/mL fraction) contain high concentrations of KBr, it is necessary to remove them by dialysis.

  1. Transfer the density fractions to a dialysis tubing and clip both ends with closures.
  2. Dialyze against 2 L of dialysis buffer such as PBS/ 1 mM EDTA for 6 h at 4 °C with agitation using a magnetic stirrer.
  3. Replace with new buffer and dialyze again for another 6 h at 4 °C.
  4. Collect the density fractions and measure the volume. Adjust all of the density fractions to the same volume (e.g., 250 µL).
    NOTE: You can calculate the concentrated factor from 1 mL of original plasma (e.g., 250 µL of density fraction corresponds to four times concentration).

4. Analysis of lipoproteins

NOTE: After dialysis, these lipoproteins are ready for different analyses. Lipoproteins can be evaluated by measuring either lipids or apolipoproteins or both. For measuring lipid contents such as total cholesterol (TC), triglycerides (TG), phospholipids (PL), and free cholesterol (FC) in each fraction, we use commercial enzymatic colorimetric assay kits. For analysis of apolipoproteins, we use SDS-PAGE visualized with CBB staining or Western blotting.

  1. Lipid analysis
    NOTE: Lipids such as TC, TG, PL and FC in the lipoprotein fraction can be measured using commercially available measurement kits. The procedures depend on the reagents used, so follow the instructions of each kit used. Here we show a typical microplate assay using a commercial enzymatic assay kit.
    1. Apply 8 μL of lipoprotein sample and standard calibration substance on 96-well microplate.
    2. Add 240 μL of assay reagent and mix by pipetting.
    3. Incubate at 37 °C for 10 min.
    4. Measure the OD with a microplate reader and calculate lipid concentrations.
  2. Apolipoprotein analysis
    1. SDS-PAGE and CBB staining
      1. Sample preparation: Add 10 μL of 2x Sample buffer to 10 μL of lipoprotein fraction. Heat the mixture at 80 °C for 5 min using a dry heat block.
      2. Prepare 4-20% gradient SDS-polyacrylamide gel and set up the gel on the electrophoresis chamber filled with running buffer.
      3. Load lipoprotein sample (10 μL/lane) and protein standards (5 μL/ lane) on the stacking gel.
        NOTE: If the samples are two times concentrated, an equivalent amount of 20 μL plasma will be analyzed per lane.]
      4. Run electrophoresis at 20–40 mA constant current.
      5. CBB staining: Soak the gel twice in fixing solution with gentle shaking for 10 min. Stain the gel with CBB staining solution for 30 min. Rinse the gel in distilled water to remove the excess stain. The gel is ready for photographing.
    2. Western blotting
      1. Perform electrophoresis in the same procedure as described above.
        NOTE: The volume of lipoproteins loaded for the Western blotting is less than for CBB staining described above (e.g. 1–5 μL).
      2. Place the gel and PVDF membrane between transfer buffer-soaked filter paper and form pad. Set up the sandwich in a holder cassette and place in a tank filled with transfer buffer.
      3. Perform electroblotting at 100 mA constant current for 3 h at 4 °C.
      4. Blocking: Incubate the membrane in blocking buffer for 1 h at room temperature or overnight at 4 °C.
      5. Primary Ab reaction: Incubate the membranes in the primary Abs diluted with blocking buffer for 1 h at room temperature or overnight at 4 °C with mild shaking.
        NOTE: Suggested primary Ab dilution is shown in the Table of Materials. Three kinds of primary Abs against apolipoproteins can be used singly or in cocktails.
      6. Wash the membrane three times in washing buffer with agitation, 5 min per wash.
      7. Secondary Ab reaction: Incubate the membrane in the secondary Abs diluted with blocking buffer for 1 h at room temperature with agitation.
        NOTE: Suggested secondary Ab dilution is shown in the Table of Materials.
      8. Wash the membrane three times in washing buffer with agitation, 5 min per wash.
      9. ECL detection: Place the membrane on a plastic wrap. Add ECL detection reagents and incubate for 1 min. Drain excess liquid and seal the membrane in a bag.
      10. Visualize the signals using an image analyzer.

Wyniki

Using this protocol, we isolated rabbit lipoproteins using 1 mL of plasma and obtained seven density fractions. Isolated density fractions are enough for measuring lipids and apolipoproteins as described above for most research purposes. The same procedure can also be used for isolating plasma lipoproteins from human and other species. For small-sized animals such as mice, pooled plasma is required. Figure 3 shows lipoprotein profiles of wild-type (WT) rabbits fed either a normal standard (N...

Dyskusje

Hyperlipidemia is one of the most important risk factors of atherosclerotic disease. Thus, analysis of plasma lipoproteins is not only essential for diagnosis of dyslipidemia patients but also important for investigation of molecular mechanisms of lipoprotein metabolism and atherosclerosis. In this study, we described the protocol of isolation and analysis of plasma lipoproteins which can be applied in the laboratories where ultracentrifugation is available. Information obtained by this method is comprehensive and straig...

Ujawnienia

The authors have nothing to disclose.

Podziękowania

This work was supported in part by a research grants from JSPS KAKENHI Grant Number JP 20K08858, the National Natural Science Foundation of China (No. 81941001 and 81770457), JSPS-CAS under the Japan-China Research Cooperative Program.

Materiały

NameCompanyCatalog NumberComments
22-gauge needleTerumoNN-2232SFor blood collection
96-well microplategreiner bio-one655101For lipids measurment
Anti-apolipoprotein A-I antibodyLifeSpan BioSciencesLS-C314186For Western blottng, use 1:1,000
Anti-apolipoprotein B antibodyROCKLAND600-101-111For Western blottng, use 1:1,000
Anti-apolipoprotein E antibodyMerck MilliporeAB947For Western blottng, use 1:1,000
CBB staining kitFUJIFILM Wako Pure Chemical299-50101For apolipoprotein analysis
CentrifugeHITACHIhimac CF15RN
ClosureSpectrum132736For lipoprotein dialysis
Dialysis tubingFUJIFILM Wako Pure Chemical043-30921For lipoprotein dialysis, MWCO 14,000
Dry heat blockMajor ScienceMD-01NFor SDS-PAGE sample preparation
ECL Western blotting detection reagentsGE HealthcareRPN2209For Western blotting
Electrophoresis ChamberBIO-RADMini-PROTEAN Tetra Cell
Ethylenediamine-N,N,N',N'-tetraacetic acid (EDTA) disodium salt dihydrateFUJIFILM Wako Pure Chemical345-01865For anticoagulant (0.5 M), for dialysis (1 mM)
Filter paperADVANTEC590For Western blotting
Fixed angle ultracentrifuge rotorBECKMAN COULTER357656TLA-120.2
Fixing solutionFor SDS-PAGE (50% Methanol/ 10% Acetic acid)
Immun-Blot PVDF menbraneBIO-RAD1620177For Western blotting
Lumino image analyzerGE HealthcareFor Western blotting, ImageQuant LAS 4000
Magnetic stirrerADVANTECSR-304For lipoprotein dialysis
Microplate reader iMARKBIO-RADFor lipids measurment
MicrotubeINA-OPTIKASC-0150
Orbital agitator USBDboStovall Life Science
Peroxidase congugated anti goat IgG antibodyJackson ImmunoResearch705-035-003For Western blotting, use 1:2,000
Peroxidase congugated anti mouse IgG antibodyJackson ImmunoResearch715-035-150For Western blotting, use 1:2,000
Phospholipids assay kitFUJIFILM Wako Pure Chemical433-36201For lipids measurment
Polycarbonate ultracentrifuge TubesBECKMAN COULTER343778
Potassium BromideFUJIFILM Wako Pure Chemical168-03475For density solution
Power SupplyBIO-RADFor SDD-PAGE and Western blotting, PowerPac 300, PowerPac HC
Protein standards Precidion Plus Protein Dual XtraBIO-RAD161-0377For SDS-PAGE and Western blotting
Rabbit restrainerNatsume SeisakushoKN-318For blood collection
RotorHITACHIT15A43
SDS-PAGE running buffer25 mM Tris/ 192 mM Glycine/ 0.1% SDS
SDS-PAGE sample buffer (2x)0.1M Tris-HCl (pH 6.8)/ 4% SDS/ 20% glycerol/ 0.01% BPB/12% 2-merpaptoethanol
SDS-polyacrylamide gel4-20% gradient polyacrylamide gel
Skim milk powderFUJIFILM Wako Pure Chemical190-12865For Western blotting blocking buffer (5% skim milk/ 0.1% Tween 20/ PBS)
Total cholesterol assay kitFUJIFILM Wako Pure Chemical439-17501For lipids measurment
Triglyicerides assay kitFUJIFILM Wako Pure Chemical432-40201For lipids measurment
Tube slicer for thick-walled tubeBECKMAN COULTER347960For lipoprotein isolation
Tween 20SIGMA-ALDRICHP1379For Western blotting washing buffer (0.1% Tween 20/ PBS)
UltracentrifugeBECKMAN COULTERA95761Optima MAX-TL
Western blotting wet transfer systemBIO-RADMini Trans-Blot Cell

Odniesienia

  1. Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., Dawber, T. R. High density lipoprotein as a protective factor against coronary heart disease: The Framingham study. The American Journal of Medicine. 62 (5), 707-714 (1977).
  2. Baigent, C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 366 (9493), 1267-1278 (2005).
  3. Nauck, M., Warnick, G. R., Rifai, N. Methods for Measurement of LDL-Cholesterol: A Critical Assessment of Direct Measurement by Homogeneous Assays versus Calculation. Clinical Chemistry. 48 (2), 236-254 (2002).
  4. Warnick, G. R., Nauck, M., Rifai, N. Evolution of Methods for Measurement of HDL-Cholesterol: From Ultracentrifugation to Homogeneous Assays. Clinical Chemistry. 47 (9), 1579-1596 (2001).
  5. Havel, R. J., Eder, H. A., Bragdon, J. H. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. The Journal of Clinical Investigation. 34 (9), 1345-1353 (1955).
  6. Hatch, F. T., Lees, R. S. Practical Methods for Plasma Lipoprotein Analysis. Advances in Lipid Research. 6, 1-68 (1968).
  7. Lindgren, F. T., Adamson, G. L., Jenson, L. C., Wood, P. D. Lipid and lipoprotein measurements in a normal adult American population. Lipids. 10 (12), 750-756 (1975).
  8. Fan, J., et al. Overexpression of hepatic lipase in transgenic rabbits leads to a marked reduction of plasma high density lipoproteins and intermediate density lipoproteins. Proceedings of the National Academy of Sciences of the United States of America. 91, 8724-8728 (1994).
  9. Wang, Y., et al. Human Apolipoprotein A-II Protects Against Diet-Induced Atherosclerosis in Transgenic Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology. 33 (2), 224-231 (2013).
  10. Niimi, M., et al. ApoE knockout rabbits: A novel model for the study of human hyperlipidemia. Atherosclerosis. 245, 187-193 (2016).
  11. Zhang, J., et al. Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in RabbitsHighlights. Arteriosclerosis, Thrombosis, and Vascular Biology. 37 (6), 1068-1075 (2017).
  12. Yan, H., et al. Endothelial Lipase Exerts its Anti-Atherogenic Effect through Increased Catabolism of β-VLDLs. Journal of Atherosclerosis and Thrombosis. 40 (9), 2095-2107 (2020).
  13. Fan, J., et al. Overexpression of Lipoprotein Lipase in Transgenic Rabbits Inhibits Diet-induced Hypercholesterolemia and Atherosclerosis. Journal of Biological Chemistry. 276 (43), 40071-40079 (2001).
  14. Koike, T., et al. Expression of Human ApoAII in Transgenic Rabbits Leads to Dyslipidemia: A New Model for Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 29 (12), 2047-2053 (2009).
  15. Ichikawa, T., et al. Overexpression of lipoprotein lipase in transgenic rabbits leads to increased small dense LDL in plasma and promotes atherosclerosis. Laboratory investigation; a Journal of Technical Methods and Pathology. 84 (6), 715-726 (2004).
  16. von Zychlinski, A., Kleffmann, T. Dissecting the proteome of lipoproteins: New biomarkers for cardiovascular diseases. Translational Proteomics. 7, 30-39 (2015).
  17. Yan, H., et al. Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology. 28 (2), 157-168 (2021).
  18. Kang, I., Park, M., Yang, S. J., Lee, M. Lipoprotein Lipase Inhibitor, Nordihydroguaiaretic Acid, Aggravates Metabolic Phenotypes and Alters HDL Particle Size in the Western Diet-Fed db/db Mice. International Journal of Molecular Sciences. 20 (12), 3057 (2019).
  19. De Silva, H. V., et al. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. Journal of Biological Chemistry. 269 (3), 2324-2335 (1994).
  20. Usui, S., Hara, Y., Hosaki, S., Okazaki, M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. Journal of Lipid Research. 43 (5), 805-814 (2002).

Przedruki i uprawnienia

Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE

Zapytaj o uprawnienia

Przeglądaj więcej artyków

Plasma LipoproteinsUltracentrifugationHyperlipidemiaAtherosclerosisDyslipidemiaLipoprotein FractionsApolipoproteinsDensity SolutionsLipoprotein ProfilesCholesterol DietTriglyceridesHDLLDLVLDLLipid Analysis

This article has been published

Video Coming Soon

JoVE Logo

Prywatność

Warunki Korzystania

Zasady

Badania

Edukacja

O JoVE

Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone